Rebecca Boardley

Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

Aili L. Lazaar, Lucy Yang, Rebecca Boardley et al. · British Journal of Clinical Pharmacology · 2015 · 171 citations · Full text

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

Richard Grove, Conn Harrington, Andreas Mahler et al. · Current Alzheimer Research · 2014 · 108 citations

The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation

Pradeep J. Nathan, Rebecca Boardley, Nicola Scott et al. · Current Alzheimer Research · 2013 · 68 citations

Unexpectedly high affinity of a novel histamine<scp>H₃</scp>receptor antagonist,<scp>GSK239512</scp>,<i>in vivo</i>in human brain, determined using<scp>PET</scp>

Sharon Ashworth, Aliénor Berges, Eugenii A. Rabiner et al. · British Journal of Pharmacology · 2013 · 39 citations · Full text

The improved efficacy of a fixed‐dose combination of fluticasone furoate and levocabastine relative to the individual components in the treatment of allergic rhinitis

R.D. Murdoch, Philippe Bareille, Diane M. Ignar et al. · Clinical & Experimental Allergy · 2015 · 20 citations